Retatrutide is not approved anywhere
On August 12, 2026, Eli Lilly said it filed six U.S. lawsuits against sellers of black-market retatrutide and asked platforms and payment companies to shut the trade down.
Retatrutide is an investigational molecule in Phase 3 trials for obesity, type 2 diabetes and other related indications. No medicine containing retatrutide has been approved for human use by any regulatory agency in the world. It cannot be sold to consumers.
Lilly said FDA has made clear that sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot be lawfully compounded, and that so-called research-use-only products are of unknown quality.
Lilly said it has referred more than 200 individuals and entities to FDA, the Department of Justice, state attorneys general, law enforcement, and licensing boards, and that it reported more than 14,000 websites, ads, posts and listings in over 100 countries.
Lilly quoted its chief medical officer, David A. Hyman, M.D.: “What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.”
A week earlier Lilly said it plans to submit a biologics license application in the first quarter of 2027. That is a filing plan, not an approval. See Retatrutide is not filed. Lilly says Q1 2027.
This is why a log and a library are not a shop. Peptide Vault does not sell retatrutide, or anything else. Related: Illicit GLP-1 seizures more than doubled in July.
Citations
Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take, how to mix it, or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.